文章基本信息

标题：Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
本地全文：下载
作者：Adam Ioannou ; Irene Tsappa ; Sofia Metaxa 等
期刊名称：Patient Related Outcome Measures
印刷版ISSN：1179-271X
电子版ISSN：1179-271X
出版年度：2017
卷号：8
页码：121-131
DOI：10.2147/PROM.S117549
语种：English
出版社：Dove Medical Press Ltd
摘要：Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation.
关键词：apixaban; atrial fibrillation; warfarin; stroke; bleeding